Arcus Biosciences Q3 net loss $71M; cash $950M; domvanalimab and AB521 updates

Arcus Biosciences, Inc.

2024-Q3 EPS reported -$3.07 revenue$86,000,000

Net loss of $71M in Q3 2023 vs $65M in Q3 2022; R&D expenses rose to $82M from $77M.
Cash, cash equivalents and marketable securities $950M as of Sept 30, 2023, down from $1.1B at Dec 31, 2022; cash runway into 2026.
Revenue $32M in Q3 2023, primarily from Gilead collaboration, vs $33M in Q3 2022.
EDGE-Gastric Phase 2: domvanalimab + zimberelimab + chemo showed 80% ORR in PD-L1-high tumors; maturity PFS data expected H2 2024.
AB521 Phase 1/1b: PK/PD consistent with healthy volunteers; no DLTs; ccRCC dose-expansion near completion; efficacy data later in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcus Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023 , Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001724521-23-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.